Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Hypertension
Interventions: irbesartan, placebo, PS433540; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 40
States / cities: Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more

Conditions: Moderate-severe Chronic Kidney Disease Not Treated With Dialysis, Diabetic Kidney Disease, HgbA1c Less Than 8.5
Interventions: Combined Aerobic and Resistance Exercise via videoconferencing; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 30 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: Chest Radiography, Computed Tomography, Follow-Up, Imaging Technique, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prosthesis User, Lower Limb Amputation Below Knee (Injury)
Interventions: Caesar Foot; Device
Lead sponsor: Liberating Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Sepsis, Septic Shock, Emergencies
Interventions: Septic Shock Clinical Decision Support, Clinical Diagnosis Only; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Interventions: GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Lakeland, Florida • Iowa City, Iowa • St Louis, Missouri + 7 more

Conditions: Bipolar Disorder
Interventions: cognitive-behavior therapy (CBT); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 24 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Chronic, Fatigue Syndrome, Chronic, Aging
Interventions: Otago, Gentle yogic breathing, Behavioral Activation, Caregiver Gentle yogic breathing; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 45 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Non-restorative Sleep, Healthy Volunteer
Interventions: Transcranial electrical stimulation with Temporal Interference (TES-TI); Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hematologic Malignancy
Interventions: Exercise training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stuttering, Developmental Stuttering
Interventions: High DC LIFU, Sham; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acquired Immune Deficiency Syndrome
Interventions: Lopinavir 400 mg/ritonavir 100 mg, Efavirenz; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois

Conditions: Spinal Cord Injuries
Interventions: Low-frequency Exercise, High-frequency Exercise; Other
Lead sponsor: Richard K Shields; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Drug Abuse
Interventions: brief intervention (cognitive-behavioral therapy); Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 13 Years to 19 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
Interventions: PEGPH20, Pembrolizumab; Drug · Biological
Lead sponsor: Pancreatic Cancer Research Team; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Gilbert, Arizona • Los Angeles, California • New Brunswick, New Jersey + 2 more

Conditions: Schizophrenia
Interventions: Brain Fitness Program (BFP), Cognitive Package (Cogpack), Commercial Computer Games (Sporcle); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 25 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Los Angeles, California • West Los Angeles, California

Conditions: Stroke
Interventions: Robot-Assisted Therapy (RT), Robot & Task-Oriented Training (RT-TOT); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 82 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tumors
Interventions: Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 3
States / cities: Boston, Massachusetts • Detroit, Michigan • Durham, North Carolina

Conditions: Gastrointestinal Discomfort, Digestive Well Being, Gut-related Symptoms
Interventions: Food ingredient of oyster mushroom mycelium (Pleurotus pulmonarius) and microalgae (Chlorella vulgaris); Dietary Supplement
Lead sponsor: Koralo GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Weight Loss
Interventions: High protein diet, Resistance Training (RT) Programs; Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 30 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Spinal Cord Injuries
Interventions: Behavioral Interaction Conditions, Haptic Impedance Level, Skill Level of Partner, Robot Controller Showcase; Behavioral · Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 80 Years
Enrollment: 764 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Acute, Pain, Neuropathic, Analgesia, Aerobic Exercise, Exercise Training
Interventions: Aerobic Exercise Training, Interval Training; Other
Lead sponsor: Georgia State University; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: HIV-1 Immunogen; Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Exercise Study Testing Enhanced Energetics of Mitochondria Video Integrated Delivery of Activity Training in CKD

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Caesar Foot Take-Home Validation Testing

Implementation Trial of Predictive Modeling to Enhance Diagnosis and Improve Treatment in Pediatric Septic Shock

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Cognitive-Behavior Therapy for Young Adults With Bipolar Disorder

Activate For Life: mHealth Intervention To Address Pain And Fatigue In Low-income Older Adults Aging In Place

Power Nap With TES-TI

Survivorship Post-HCT Optimization Program

Noninvasive Thalamocortical Neuromodulation With Low-Intensity Focused Ultrasound for Persistent Developmental Stuttering

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Long Duration Activity and Metabolic Control After Spinal Cord Injury

Brief Intervention for Drug Abusing Adolescents

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia

Robot-Assisted Therapy and Motor Learning: An Active Learning Program for Stroke

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris)

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

Human-like Robotic Controllers for Enhanced Motor Learning

Exercise and Pain in Non-Hispanic Blacks and Whites

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)